TNF and rheumatoid arthritis: The Kaplan–Meier curve analysis showed no significant differences in drug discontinuation rates for each b/tsDMARD (p = 0.27), while drug switching rates differed among Janus kinase (JAK) inhibitors, tocilizumab, abatacept, tumor necrosis factor (TNF) inhibitors, and rituximab (p < 0.001) in patients with D2T RA (Fig. 2).